Victor Duque Santana, Radiation Oncologist at University Hospital Quironsalud Madrid, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“This is how we manage high-risk prostate cancer in Spain.
Proud to share our latest work: ‘Management of High-Risk Prostate Cancer in Spain: Results from a National Patterns-of-Care Survey’, now published in Clinical and Translational Oncology.
This nationwide URONCOR pattern of care survey collected responses from 74 radiation oncologists across 71 hospitals, providing a comprehensive overview of contemporary clinical practice across Spain.
Key insights from the study:
- Great heterogeneity in radiotherapy treatments, with 26 fractionation regimens reported, moderate hypofractionation being the most commonly used
- Brachytherapy boost remains common, though with significant variability in dose and technique.
- Whole-pelvis radiotherapy is performed in 55% of centres, highlighting ongoing debate regarding patient selection.
- PSMA-PET adoption is still limited (28.4% at diagnosis).
- 24 months of ADT is the most frequent systemic approach
- 76% prescribe abiraterone for very high-risk patients.
- For local recurrence, HDR-brachytherapy is the preferred re-irradiation strategy, despite wide variation in schedules.
Why this matters:
Our findings highlight the need for national consensus guidelines to standardize the management of high-risk prostate cancer in Spain.
Grateful to all URONCOR investigators for their invaluable contribution.”
Title: Management of high-risk prostate cancer in Spain: results from a national patterns of care survey
Authors: Victor Duque-Santana, Maria Antonia Gómez-Aparicio, Abrahams Ocanto, Elias Gomis Selles, Miren Gaztañaga, Patricia Willisch, Xavier Maldonado Pijoan, Manuel Luis Blanco-Villar, Ivan Henriquez, Pedro Carlos Lara, Ivone Ribeiro, Alai Goñi Ramirez, Marta López Valcárcel, Ignacio Visus Fernández de Manzanos, Susana Pérez Echagüen, Pilar Alonso Martínez, Victoria Vera Barragán, Carmen Velilla Millán, Ana Illescas Vacas, Pilar María Samper Ots, Luis Alberto Glaría Enríquez, Angel Montero Luis, Laura Montezuma Niño, Rocío del Castillo Acuña, Elísabet González Del Portillo, Ferran Ferrer, Alfonso Gómez-Iturriaga, Antonio José Conde Moreno, Elia Del Cerro Peñalver, Felipe Couñago, Fernando López-Campos, URONCOR investigators
Read the Full Article on Clinical and Translational Oncology
More posts featuring Victor Duque Santana.